Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD Pharmaceutical TechnologyOutlook's approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD.OphthalmologyRead full story pharminent July 27, 2026 (Last updated: July 28, 2026) Pharmaceutical Technology Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD. Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: D.C. Circuit Affirms HHS Authority Over 340B Rebate ModelsNext: Outlook finally claims FDA approval for AMD drug Related Stories Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide pharminent July 23, 2026 Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug pharminent July 23, 2026
